Ublituximab Market Forecasted to Reach USD $2.24 Billion by 2030 at 12.3% CAGR

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Are the Projections for Ublituximab Market Size and CAGR During 2026-2030?
The ublituximab market size has grown rapidly in recent years. It will grow from $1.25 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to advances in monoclonal antibody development, increasing prevalence of b-cell related disorders, expansion of biologics manufacturing capacity, regulatory approvals for cd20 therapies, growth in immuno-oncology research.

The ublituximab market size is expected to see rapid growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing development of next-generation antibodies, rising focus on treatment durability and safety, expansion into autoimmune indications, growing investments in biologics manufacturing innovation, increasing adoption of precision immunotherapy. Major trends in the forecast period include increasing adoption of cd20-targeted monoclonal antibodies, rising focus on b-cell depletion therapies, growing use of immune-modulating treatments, expansion of combination antibody regimens, enhanced optimization of antibody engineering.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/ublituximab-global-market-report

What Are the Primary Growth Contributors in the Ublituximab Market?
The rising incidence of autoimmune disorders is expected to propel the growth of the ublituximab market going forward. Autoimmune disorders are conditions where the immune system mistakenly attacks healthy cells or where blood cell production and function are impaired, respectively. The increasing prevalence of these disorders is primarily driven by improved diagnostic capabilities and awareness, as healthcare systems are now better equipped to identify previously undiagnosed cases through advanced testing methods and expanded screening programs. Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, helps manage autoimmune disorders by selectively depleting pathogenic B cells, thereby reducing aberrant immune activity and malignant cell proliferation. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the rising incidence of autoimmune disorders is driving the growth of the ublituximab market.

What Are the Main Segments of the Ublituximab Market?
The ublituximab market covered in this report is segmented –

1) By Formulation Type: Intravenous, Pre-Filled Syringes
2) By Indication: Chronic Lymphocytic Leukemia, Multiple Sclerosis, Non-Hodgkin Lymphoma
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Research Institutes

Subsegments:
1) By Intravenous: Single Dose Vials, Multi Dose Vials, Lyophilized Powder, Liquid Solution
2) By Pre Filled Syringes: Standard Pre Filled Syringes, Safety Engineered Pre Filled Syringes, Disposable Pre Filled Syringes, Reusable Pre Filled Syringes

What Are the Major Trends Impacting the Ublituximab Market?
Major companies operating in the ublituximab market are focusing on developing innovative products such as next-generation monoclonal antibodies to improve efficacy, reduce side effects, and enhance patient convenience. Next-generation monoclonal antibodies are engineered antibodies with improved targeting, potency, or safety profiles, helping enhance treatment effectiveness, minimize side effects, and offer more convenient dosing. For instance, in January 2023, TG Therapeutics Inc., a US-based biopharmaceutical company, launched BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, offering a one-hour infusion option and an extensive patient support program to improve accessibility and treatment adherence. The drug is a glycoengineered anti-CD20 monoclonal antibody designed to efficiently deplete B-cells, reducing relapse rates and disease activity in patients with RMS, while also minimizing potential side effects and providing a more convenient dosing schedule compared to traditional therapies. Its mechanism of action involves binding to a specific epitope on CD20-expressing B-cells, resulting to their targeted depletion through antibody-dependent cellular cytotoxicity (ADCC) and apoptosis, which helps modulate the autoimmune response underlying multiple sclerosis.

Who Are the Leading Companies in the Ublituximab Industry by Revenue?
Major companies operating in the ublituximab market are Samsung Biologics Co. Ltd., TG Therapeutics Inc.

Get the full ublituximab market report here:
https://www.thebusinessresearchcompany.com/report/ublituximab-global-market-report

Which region represents the fastest-growing market for the Ublituximab Market?
North America was the largest region in the ublituximab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ublituximab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn